|
ISRCTN
|
ISRCTN68939136
|
|
ClinicalTrials.gov identifier
|
|
|
Public title
|
Imaging the neural correlates of rehabilitation in Wernicke's aphasia
|
|
Scientific title
|
Imaging the neural correlates of cholinergic and behaviour driven rehabilitation in patients with Wernicke's aphasia: a double-blinded, cross-over, randomised controlled trial
|
|
Acronym
|
N/A
|
|
Serial number at source
|
075765; ME033459MES
|
|
Study hypothesis
|
To measure therapy related changes in brain function in a group of patients with post-stroke, Wernicke's aphasia. Two therapies will be trialed: a drug (donepezil) and computer delivered speech therapy programme.
|
|
Ethics approval
|
Approval received from the local COREC committee (National Hospital for Neurology and Neurosurgery and the Institute of Neurology Joint REC) on the 6th January 2006 (ref: 05/Q0512/134).
|
|
Study design
|
A double-blinded, cross-over, randomised controlled trial
|
|
Countries of recruitment
|
United Kingdom
|
|
Disease/condition/study domain
|
Post-stroke aphasia
|
|
Participants - inclusion criteria
|
1. Subjects will be English native speakers
2. Subjects will be over the age of 18, either sex
3. More than three months post stroke
4. Only consent competent patients will be enrolled
|
|
Participants - exclusion criteria
|
1. Patients with contraindications to cholinesterase inhibitors
2. Patients with contraindications to functional Magnetic Resonance Imaging (fMRI)/Magnetoencephalography (MEG)
3. Significant medical or psychiatric co-morbidity
4. Under 18 years old
|
|
Anticipated start date
|
01/10/2006
|
|
Anticipated end date
|
30/07/2009
|
|
Status of trial
|
Completed |
|
Patient information material
|
Not available in web format, please use the contact details below to request a patient information sheet
|
|
Target number of participants
|
~30
|
|
Interventions
|
This is a cross-over trial. Each patient will be randomised to one of the two groups:
Group one: Donezepil (5 mg) once daily (od) for five weeks (block one), if this is well tolerated then this will be increased to 10 mg od for five weeks (block two).
Group two: An identical placebo will be provided, to be used in the exact same method as above (blocks four and five).
In between the two groups (block three), there will be a washout period of five weeks.
At blocks two and five, a non drug intervention will also be supplied. During these times, a five week Behavioural Therapy (BT) treatment will also be provided, which will be performed by the patients at their home, and will consist of 30 minutes of a computer-based phonological training program once a day.
|
|
Primary outcome measure(s)
|
Correlation between treatment type and changes in the response characteristics of a neurophysiologic measure of auditory discrimination (Mismatch Negativity [MMN]), provoked by language and non-language stimuli, measured using both MEG and fMRI.
|
|
Secondary outcome measure(s)
|
Correlation between treatment type and improvements on a language rating scale: the Comprehensive Aphasia Test.
|
|
Sources of funding
|
The Wellcome Trust (UK) (grant ref: 075765) - Intermediate Clinical Fellowship
|
|
Trial website
|
|
|
Publications
|
|
|
Contact name
|
Dr
Alexander Paul
Leff
|
|
Address
|
Wellcome Department of Imaging Neuroscience
12 Queen Square
|
|
City/town
|
London
|
|
Zip/Postcode
|
WC1N 3BG
|
|
Country
|
United Kingdom
|
|
Tel
|
+44 (0)20 7833 7472
|
|
Fax
|
+44 (0)20 7833 7472
|
|
Email
|
a.leff@fil.ion.ucl.ac.uk
|
|
Sponsor
|
Joint UCLH and UCL Biomedical Research Unit (UK)
|
|
Address
|
c/o Dr Victoria Latter, Operations Director
1st Floor, Maple House
149 Tottenham Court Road
|
|
City/town
|
London
|
|
Zip/Postcode
|
W1P 9LL
|
|
Country
|
United Kingdom
|
|
Tel
|
+44 (0)20 7472 6394
|
|
Email
|
v.latter@medsch.ucl.ac.uk
|
|
Sponsor website:
|
http://www.ucl.ac.uk/biomed-r-d/general/about_us.htm#contact
|
|
Date applied
|
10/11/2006
|
|
Last edited
|
26/01/2009
|
|
Date ISRCTN assigned
|
04/12/2006
|
